Clinical Trials Logo

ERBB2 Gene Amplification clinical trials

View clinical trials related to ERBB2 Gene Amplification.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02004769 Completed - Stomach Neoplasms Clinical Trials

Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer

Start date: November 2013
Phase: Phase 2
Study type: Interventional

Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease are to be recruited in the study. In the current study, the efficacy and safety of Trastuzumab in combination with Capecitabine/Docetaxel will be evaluated in Chinese patients with HER2 positive advanced or recurrent gastric cancer.60 patients could provide adequate precision rather than controlling type I&II error. Assuming the target PFS is 6.7m, 60 patients will give 90% CI of (5.5, 8.4). Considering the 5% drop out rate, 65 patients will be enrolled.

NCT ID: NCT00006089 Completed - Clinical trials for Endometrial Adenocarcinoma

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Start date: September 18, 2000
Phase: Phase 2
Study type: Interventional

Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase II trial to study the effectiveness of trastuzumab in treating patients who have stage III, stage IV, or recurrent endometrial cancer.